27-Jan-2025
No headlines found.
Globe Newswire (Tue, 17-Dec 6:30 AM ET)
Globe Newswire (Mon, 9-Dec 1:30 PM ET)
Globe Newswire (Mon, 9-Dec 6:30 AM ET)
Globe Newswire (Sun, 8-Dec 12:00 PM ET)
Globe Newswire (Thu, 5-Dec 6:30 AM ET)
Affimed Reports Third Quarter 2024 Financial Results & Business Update
Globe Newswire (Thu, 14-Nov 6:30 AM ET)
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
Globe Newswire (Wed, 6-Nov 6:30 AM ET)
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The Company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
Affimed N.V. trades on the NASDAQ stock market under the symbol AFMD.
As of January 27, 2025, AFMD stock price declined to $1.02 with 488,426 million shares trading.
AFMD has a beta of 2.56, meaning it tends to be more sensitive to market movements. AFMD has a correlation of 0.10 to the broad based SPY ETF.
AFMD has a market cap of $15.53 million. This is considered a Sub-Micro Cap stock.
Last quarter Affimed N.V. reported $170,361 in Revenue and -$1.03 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.08.
In the last 3 years, AFMD traded as high as $51.00 and as low as $.93.
AFMD has underperformed the market in the last year with a price return of -82.0% while the SPY ETF gained +24.4%. AFMD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -69.3% and -8.9%, respectively, while the SPY returned +3.9% and +3.1%, respectively.
AFMD support price is $1.03 and resistance is $1.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AFMD shares will trade within this expected range on the day.